Loading...

VBI Vaccines

DB:LO91
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LO91
DB
$194M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The last earnings update was 59 days ago. More info.


Add to Portfolio Compare Print
  • VBI Vaccines has significant price volatility in the past 3 months.
LO91 Share Price and Events
7 Day Returns
4.1%
DB:LO91
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-29.7%
DB:LO91
-5.6%
DE Biotechs
-4.5%
DE Market
LO91 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
VBI Vaccines (LO91) 4.1% 14.6% 31.9% -29.7% -32.6% -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • LO91 underperformed the Biotechs industry which returned -5.6% over the past year.
  • LO91 underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
LO91
Industry
5yr Volatility vs Market
Related Companies

Value

 Is VBI Vaccines undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for VBI Vaccines. This is due to cash flow or dividend data being unavailable. The share price is €1.834.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for VBI Vaccines's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are VBI Vaccines's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:LO91 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.97
NasdaqCM:VBIV Share Price ** NasdaqCM (2019-04-25) in USD $1.95
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of VBI Vaccines.

DB:LO91 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:VBIV Share Price ÷ EPS (both in USD)

= 1.95 ÷ -0.97

-2.01x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • VBI Vaccines is loss making, we can't compare its value to the Europe Biotechs industry average.
  • VBI Vaccines is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does VBI Vaccines's expected growth come at a high price?
Raw Data
DB:LO91 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.01x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
63%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for VBI Vaccines, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on VBI Vaccines's assets?
Raw Data
DB:LO91 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.01
NasdaqCM:VBIV Share Price * NasdaqCM (2019-04-25) in USD $1.95
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:LO91 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:VBIV Share Price ÷ Book Value per Share (both in USD)

= 1.95 ÷ 1.01

1.93x

* Primary Listing of VBI Vaccines.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • VBI Vaccines is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess VBI Vaccines's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. VBI Vaccines has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is VBI Vaccines expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
63%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is VBI Vaccines expected to grow at an attractive rate?
  • VBI Vaccines's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • VBI Vaccines's earnings growth is expected to exceed the Germany market average.
  • VBI Vaccines's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:LO91 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:LO91 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 63%
DB:LO91 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 49.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:LO91 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:LO91 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 271 134 119 2
2022-12-31 186 9 66 2
2021-12-31 123 -31 12 2
2020-12-31 50 -41 -30 3
2019-12-31 1 -63 -60 2
DB:LO91 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 3 -46 -64
2018-09-30 1 -47 -56
2018-06-30 1 -40 -50
2018-03-31 1 -32 -43
2017-12-31 1 -31 -39
2017-09-30 1 -30 -36
2017-06-30 1 -28 -33
2017-03-31 1 -25 -31
2016-12-31 1 -19 -23
2016-09-30 0 -14 -19
2016-06-30 0 -14 -31
2016-03-31 1 -9 -25

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • VBI Vaccines's earnings are expected to grow significantly at over 20% yearly.
  • VBI Vaccines's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:LO91 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from VBI Vaccines Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LO91 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.94 1.07 0.81 2.00
2022-12-31 0.54 0.55 0.52 2.00
2021-12-31 0.14 0.27 0.00 2.00
2020-12-31 -0.24 -0.02 -0.44 3.00
2019-12-31 -0.56 -0.54 -0.58 2.00
DB:LO91 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.97
2018-09-30 -0.90
2018-06-30 -0.89
2018-03-31 -0.85
2017-12-31 -0.88
2017-09-30 -0.91
2017-06-30 -0.87
2017-03-31 -0.87
2016-12-31 -0.77
2016-09-30 -0.75
2016-06-30 -1.48
2016-03-31 -1.62

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if VBI Vaccines will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess VBI Vaccines's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
VBI Vaccines has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has VBI Vaccines performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare VBI Vaccines's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • VBI Vaccines does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare VBI Vaccines's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare VBI Vaccines's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
VBI Vaccines's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from VBI Vaccines Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LO91 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 3.36 -63.60 20.51 38.47
2018-09-30 0.87 -55.89 14.35 34.62
2018-06-30 0.81 -50.33 13.35 29.32
2018-03-31 0.92 -42.61 12.41 22.93
2017-12-31 0.87 -39.00 12.03 20.92
2017-09-30 0.80 -35.86 9.28 18.61
2017-06-30 0.89 -33.36 9.94 16.77
2017-03-31 0.63 -30.76 10.31 14.37
2016-12-31 0.55 -23.21 9.24 9.97
2016-09-30 0.40 -18.97 8.51 6.03
2016-06-30 0.22 -30.82 8.10 16.27
2016-03-31 0.58 -25.44 5.95 14.26
2015-12-31 0.96 -26.19 4.71 0.62
2015-09-30 2.10 -23.04 5.21 13.95
2015-06-30 2.38 -6.22 3.12 0.60
2015-03-31 2.39 -6.46 2.77 0.63
2014-12-31 2.87 -5.67 2.73 0.63
2013-12-31 1.66 -8.86 2.85 0.61
2012-12-31 2.90 -0.68 2.58 0.58

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if VBI Vaccines has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if VBI Vaccines has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if VBI Vaccines improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess VBI Vaccines's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
VBI Vaccines has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is VBI Vaccines's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up VBI Vaccines's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • VBI Vaccines is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • VBI Vaccines's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of VBI Vaccines's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 4.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from VBI Vaccines Company Filings, last reported 3 months ago.

DB:LO91 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 98.13 14.03 59.27
2018-09-30 77.13 13.68 25.99
2018-06-30 89.80 13.73 41.13
2018-03-31 106.46 13.44 58.09
2017-12-31 119.79 13.14 67.69
2017-09-30 62.97 12.84 10.05
2017-06-30 69.36 12.54 15.64
2017-03-31 75.86 12.24 23.51
2016-12-31 83.73 11.96 32.28
2016-09-30 79.50 2.00 16.72
2016-06-30 86.54 2.21 21.81
2016-03-31 10.42 0.00 10.96
2015-12-31 12.19 0.00 12.48
2015-09-30 29.42 0.00 16.01
2015-06-30 -12.20 11.74 0.02
2015-03-31 -10.76 10.81 0.30
2014-12-31 -9.41 9.78 0.52
2013-12-31 -30.62 28.04 0.03
2012-12-31
  • VBI Vaccines's level of debt (14.3%) compared to net worth is satisfactory (less than 40%).
  • VBI Vaccines had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • VBI Vaccines has sufficient cash runway for 1.2 years based on current free cash flow.
  • VBI Vaccines has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 51.5% each year.
X
Financial health checks
We assess VBI Vaccines's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. VBI Vaccines has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is VBI Vaccines's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from VBI Vaccines dividends.
If you bought €2,000 of VBI Vaccines shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate VBI Vaccines's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate VBI Vaccines's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:LO91 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:LO91 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as VBI Vaccines has not reported any payouts.
  • Unable to verify if VBI Vaccines's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of VBI Vaccines's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as VBI Vaccines has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess VBI Vaccines's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can VBI Vaccines afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. VBI Vaccines has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of VBI Vaccines's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jeff Baxter
COMPENSATION $826,044
AGE 57
TENURE AS CEO 2.9 years
CEO Bio

Mr. Jeff R. Baxter, FCMA has been the Chief Executive Officer and President of VBI Vaccines Inc. since 2009. Mr. Baxter has been the Chief Executive Officer and President of VBI DE since July 2014. He has been the Chief Executive Officer of VBI US since September 2009. He has more than two decades of outstanding success in the biotechnology and pharmaceuticals industries. In his 19 years of pharma experience, he has experience ranging from management operations to finance and business development and venture capital and has held line management roles in commercial, manufacturing, information technology and the office of the Chief Executive Officer. He served as a Managing Partner at The Column Group LLC. He played a pivotal role in the creation of Immune Design Corp. Mr. Baxter served as Senior Vice President of Research & Development and Finance & Operations, Vice President of Competitive Excellence and Head of Finance, Worldwide Manufacturing & Supply and Chairman of Research and Development Operating Board/Senior Vice President of R&D Finance and Operations at GlaxoSmithKline plc (GSK) until July 2006. He served at Unilever plc and British American Tobacco Plc. Mr. Baxter’s most recent position from 2002 to 2006 in research and development included responsibility for finance, pipeline resource planning and allocation, business development deal structuring and SROne. He also chaired GSK’s Research and Development Operating Board. He has been a Director of VBI Vaccines Inc. since 2009, VBI DE since July 2014 and VBI US since September 2009. He has been a Non Executive Director of ChromaDex Corporation since April 16, 2015. He has been a Director of SciVac Therapeutics Inc since May 6, 2016. He is a Fellow of the Chartered Institute of Management Accountants (FCMA). Mr. Baxter was educated at Thames Valley University, University of Bradford Management School and London Business School.

CEO Compensation
  • Jeff's compensation has been consistent with company performance over the past year.
  • Jeff's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the VBI Vaccines management team in years:

2.1
Average Tenure
53
Average Age
  • The tenure for the VBI Vaccines management team is about average.
Management Team

Jeff Baxter

TITLE
CEO, President & Director
COMPENSATION
$826K
AGE
57
TENURE
2.9 yrs

David Anderson

TITLE
Chief Scientific Officer
COMPENSATION
$521K
AGE
48
TENURE
2.9 yrs

Francisco Diaz-Mitoma

TITLE
Chief Medical Officer
COMPENSATION
$649K
AGE
63
TENURE
3.2 yrs

Chris McNulty

TITLE
CFO & Head of Business Development
AGE
41
TENURE
0.7 yrs

Athena Kartsaklis

TITLE
Senior VP of Finance
AGE
53
TENURE
1.6 yrs

Nell Beattie

TITLE
Chief Business Officer
AGE
30
TENURE
1.6 yrs

Avi Mazaltov

TITLE
Global Head of Manufacturing & GM of SciVac Manufacturing Site - Rehovot
AGE
56
TENURE
2.1 yrs
Board of Directors Tenure

Average tenure and age of the VBI Vaccines board of directors in years:

1.3
Average Tenure
67
Average Age
  • The average tenure for the VBI Vaccines board of directors is less than 3 years, this suggests a new board.
Board of Directors

Steve Gillis

TITLE
Chairman
COMPENSATION
$126K
AGE
65
TENURE
2.9 yrs

Jeff Baxter

TITLE
CEO, President & Director
COMPENSATION
$826K
AGE
57
TENURE
2.9 yrs

Michel De Wilde

TITLE
Independent Director
COMPENSATION
$85K
AGE
69
TENURE
2.9 yrs

Stanley Plotkin

TITLE
Member of Scientific Advisory Board
AGE
85

Denis Burger

TITLE
Member of Scientific Advisory Board
AGE
74

Tomer Kariv

TITLE
Director
AGE
57
TENURE
1.3 yrs

Robert Pass

TITLE
Member of Scientific Advisory Board
TENURE
1.3 yrs

Adam Finn

TITLE
Member of Scientific Advisory Board
TENURE
1.3 yrs

Peter Patriarca

TITLE
Member of Scientific Advisory Board
TENURE
1.3 yrs

Daniel Shouval

TITLE
Member of Scientific Advisory Board
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Dec 18 Buy Pontifax Ltd. Company 17. Dec 18 17. Dec 18 185,714 €1.23 €229,190
18. Dec 18 Buy Ran Nussbaum Individual 17. Dec 18 17. Dec 18 1,242,857 €1.23 €1,533,810
17. Dec 18 Buy Perceptive Advisors LLC Company 13. Dec 18 13. Dec 18 14,285,714 €1.23 €17,614,000
08. Aug 18 Buy Jeff Baxter Individual 06. Aug 18 06. Aug 18 8,100 €1.67 €13,489
06. Aug 18 Buy F. Diaz-Mitoma Medicine Professional Corporation Company 02. Aug 18 02. Aug 18 3,000 €1.89 €5,683
06. Aug 18 Buy F. Diaz-Mitoma Medicine Professional Corporation Company 03. Aug 18 03. Aug 18 6,000 €1.81 €10,862
06. Aug 18 Buy Jeff Baxter Individual 03. Aug 18 03. Aug 18 13,500 €1.73 €23,372
03. Aug 18 Buy Nell Beattie Individual 03. Aug 18 03. Aug 18 2,000 €1.73 €3,458
01. Aug 18 Buy Jeff Baxter Individual 31. Jul 18 31. Jul 18 16,800 €1.94 €32,673
25. May 18 Buy Jeff Baxter Individual 24. May 18 24. May 18 11,000 €2.55 €28,052
16. May 18 Buy F. Diaz-Mitoma Medicine Professional Corporation Company 11. May 18 11. May 18 5,500 €2.50 €13,732
16. May 18 Buy Jeff Baxter Individual 11. May 18 11. May 18 7,100 €2.44 €17,310
16. May 18 Buy Francisco Diaz-Mitoma Individual 11. May 18 11. May 18 4,500 €2.62 €11,800
14. May 18 Buy F. Diaz-Mitoma Medicine Professional Corporation Company 11. May 18 11. May 18 5,500 €2.50 €13,732
14. May 18 Buy Francisco Diaz-Mitoma Individual 11. May 18 11. May 18 4,500 €2.62 €11,800
14. May 18 Buy Jeff Baxter Individual 11. May 18 11. May 18 7,100 €2.44 €17,310
X
Management checks
We assess VBI Vaccines's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. VBI Vaccines has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus. It is also developing cytomegalovirus vaccine candidate for infectious disease; and glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts.

Details
Name: VBI Vaccines Inc.
LO91
Exchange: DB
Founded:
$174,484,876
97,661,887
Website: http://www.vbivaccines.com
Address: VBI Vaccines Inc.
222 Third Street,
Suite 2241,
Cambridge,
Massachusetts, 02142,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM VBIV Ordinary Shares Nasdaq Capital Market US USD 29. Dec 2009
DB LO91 Ordinary Shares Deutsche Boerse AG DE EUR 29. Dec 2009
DB LO91 COM NPV (POST REV SPLIT) Deutsche Boerse AG DE EUR 25. Apr 2019
Number of employees
Current staff
Staff numbers
110
VBI Vaccines employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 21:04
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/23
Last earnings filing: 2019/02/25
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.